Trending NewsTrending NewsTop-Rated Dividend StocksTop-Rated DividendMost-Upgraded StocksMost-UpgradedNYSE:ABBV AbbVie (ABBV) Stock Price, News & Analysis $263.24 -0.06 (-0.02%) As of 02:20 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About AbbVie Stock (NYSE:ABBV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AbbVie alerts:Sign Up Key Stats Today's Range$262.89▼$265.3650-Day Range$243.64▼$266.3952-Week Range$190.75▼$269.39Volume1.06 million shsAverage Volume6.44 million shsMarket Capitalization$465.08 billionP/E Ratio74.38Dividend Yield2.63%Price Target$272.66Consensus RatingModerate Buy Company Overview AbbVie Inc. is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health. The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care. AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories. Based in North Chicago, Illinois, the company serves patients and healthcare professionals in the United States and international markets. Robert A. Michael has served as AbbVie’s chief executive officer since July 2024.AI Generated. May Contain Errors. Read More AbbVie Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreABBV MarketRank™: AbbVie scored higher than 78% of companies evaluated by MarketBeat, and ranked 123rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.7 / 5Analyst RatingModerate Buy Consensus RatingAbbVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 2 strong buy ratings, 23 buy ratings, 6 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for AbbVie is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAbbVie has been the subject of 21 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AbbVie's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth14.80% Earnings GrowthEarnings for AbbVie are expected to grow by 14.80% in the coming year, from $14.05 to $16.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbbVie is 74.41, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.77.Price to Earnings Ratio vs. SectorThe P/E ratio of AbbVie is 74.41, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.16.Price to Earnings Growth RatioAbbVie has a PEG Ratio of 1.20. PEG Ratios above 1 indicate that a company could be overvalued.Read more about AbbVie's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.10% of the float of AbbVie has been sold short.Short Interest Ratio / Days to CoverAbbVie has a short interest ratio ("days to cover") of 4.48.Change versus previous monthShort interest in AbbVie has recently decreased by 0.10%, indicating that investor sentiment is improving. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldAbbVie pays a meaningful dividend of 2.60%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAbbVie has been increasing its dividend for 53 years.Dividend CoverageThe dividend payout ratio of AbbVie is 195.48%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, AbbVie will have a dividend payout ratio of 42.90% next year. This indicates that AbbVie will be able to sustain or increase its dividend.Read more about AbbVie's dividend. News and Social Media2.9 / 5News Sentiment0.71 News SentimentAbbVie has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 49 news articles for AbbVie this week, compared to 9 articles on an average week.Search InterestOnly 74 people have searched for ABBV on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat Follows94 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is an increase of 68% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,177,500.00 in company stock.Percentage Held by Insiders0.06% of the stock of AbbVie is held by insiders.Percentage Held by Institutions70.23% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AbbVie's insider trading history. Receive ABBV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABBV Stock News HeadlinesAbbVie Stock: Buy, Sell, or Hold in October?1 hour ago | fool.comAbbVie’s Bretisilocin Study Completion Signals Quiet Progress in Early-Stage Pipeline1 hour ago | tipranks.com"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you make with it. Using the 4% rule as a benchmark, that balance could translate to about $100,000 in year one, adjusted upward for inflation each year after. But the 4% rule has potential downsides and may not fit every portfolio. A financial advisor can help size and structure a retirement budget around your income sources, taxes, and goals. SmartAsset's free quiz matches nearly 50,000 people each month with vetted fiduciary advisors.September 30 at 1:00 AM | SmartAsset (Ad)AbbVie Wraps Key Early Trial on ABBV-722 Drug Interaction, Supporting Pipeline Confidence1 hour ago | tipranks.com3 Healthcare Dividend Stocks Offering More Than Just Income (ABBV)AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.2 hours ago | marketbeat.comAbbVie Reveals Positive Data for Eczema and Weight Loss Candidates3 hours ago | benzinga.comBofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline StrengthSeptember 30 at 7:15 AM | 247wallst.comModerna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It (ABBV)Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.September 6, 2026 | marketbeat.comSee More Headlines ABBV Stock Analysis - Frequently Asked Questions How have ABBV shares performed this year? AbbVie's stock was trading at $228.55 at the beginning of the year. Since then, ABBV shares have increased by 15.2% and is now trading at $263.3910. How were AbbVie's earnings last quarter? AbbVie Inc. (NYSE:ABBV) announced its earnings results on Friday, July, 31st. The company reported $3.65 earnings per share for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. AbbVie's quarterly revenue was up 10.2% compared to the same quarter last year. Read the conference call transcript. Does AbbVie have any subsidiaries? AbbVie subsidiaries include these companies: Mavupharma, Allergan, Stem CentRx, Pharmacyclics Inc, ImmuVen, AbbVie AB, AbbVie AG, and others. How do I buy shares of AbbVie? Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AbbVie own? Based on aggregate information from My MarketBeat watchlists, some other companies that AbbVie investors own include NVIDIA (NVDA), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), Chevron (CVX), Vanguard Short-Term Inflation-Protected Securities ETF (VTIP), Salesforce (CRM) and Intact Financial (IFC). Company Calendar Record date for 8/14 Dividend7/15/2026Ex-Dividend for 8/14 Dividend7/15/2026Last Earnings7/31/2026Dividend Payable8/14/2026Today9/30/2026Record date for 11/16 Dividend10/15/2026Ex-Dividend for 11/16 Dividend10/15/2026Next Earnings (Estimated)10/30/2026Dividend Payable11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ABBV's financial health is in the Green zone, according to TradeSmith. ABBV has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:ABBV CIK1551152 Webwww.abbvie.com Phone(847) 932-7900Fax302-655-5049Employees57,000Year Founded2013Price Target and Rating Average Price Target for AbbVie$272.66 High Price Target$315.00 Low Price Target$225.00 Potential Upside/Downside+3.4%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage31 Analysts Profitability EPS (Trailing Twelve Months)$3.54 Trailing P/E Ratio74.47 Forward P/E Ratio18.76 P/E Growth1.2Net Income$4.23 billion Net Margins9.80% Pretax Margin13.51% Return on Equity-422.07% Return on Assets14.34% Debt Debt-to-Equity RatioN/A Current Ratio0.81 Quick Ratio0.69 Sales & Book Value Annual Sales$61.16 billion Price / Sales7.62 Cash Flow$15.00 per share Price / Cash Flow17.58 Book Value($1.83) per share Price / Book-144.05Miscellaneous Outstanding Shares1,766,790,000Free Float1,765,733,000Market Cap$465.76 billion OptionableOptionable Beta0.29 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NYSE:ABBV) was last updated on 9/30/2026 by MarketBeat.com Staff. From Our PartnersSMX: From Under-the-Radar to Must-Watch!SMX (Security Matters) PLC embeds molecular-level markers into plastics, metals, fuels, and textiles, giving e...Equiscreen | SponsoredLegendary U.S. Congressman Issues WarningDr. Ron Paul warns a dangerous experiment is already underway in Washington, involving at least 27 billion dol...Altimetry | SponsoredA Little Known Explorer Sits Near Major Gold DepositsBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...Paradigm Press | SponsoredTrump Wants to Reprice America's Gold at Market ValueThe US government still values its gold reserves at 42 dollars an ounce, a price Congress set in 1973. Gold tr...Concord Gold Capital | SponsoredI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbbVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbbVie With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
